Colon and Rectal Cancer Drugs Market Opportunity Analysis, 2018 – 2026
Request Sample Copy of this Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/2019
Colon and Rectal Cancer Drugs Market – Drivers
Increasing incidence and prevalence of colon and rectal cancer, worldwide and increasing research and development studies for colorectal cancer treatment is expected to drive growth of colon and rectal cancer market in the near future. For instance, according to February 2018 data findings of the American Cancer Society (ACS), colorectal cancer is the third most common cancer diagnosed in both men and women in the U.S.
Moreover, according to the Center for Disease Control and Prevention (CDC), in 2014, around 139,992 people in the U.S. were diagnosed with colorectal cancer, including 73,396 men and 66,596 women. Among which, around 51,651 people in the U.S. died due to colorectal cancer, including 27,134 men and 24,517 women. Furthermore, according to 2012 data findings of the World Health Organization (WHO), colorectal cancer is the third most common cancer in men (746,000 cases, 10.0% of the total) and the second most common in women (614,000 cases, 9.2% of the total) worldwide, in 2012. Furthermore, around 55% of these cases occurred in developed regions.
Increasing number of research and development (R&D) studies by government and private healthcare organizations is also fueling growth of colon and rectal cancer drugs market. For instance, the American Cancer Society (ACS) spend US$ 54 million on colon and rectal cancer research involving 92 research grants, till March 2018.
Colon and Rectal Cancer Drugs Market – Restraints
Lack of development in the neoadjuvant/adjuvant pipeline agents for the treatment of high risk colorectal cancer resulted in slower growth of colon and rectal cancer drugs market. For instance, according to the data published in the National Center for Biotechnology Information (NCBI) in April 2016, there is lack of clinical trials of systemic adjuvant, neoadjuvant, and perioperative chemotherapy for the treatment of colorectal liver metastases (CRLM). These offers lucrative opportunity for the key players to develop new treatment therapy using neoadjuvant agents for resected patients.
Furthermore, improper reimbursement policies for colorectal cancer treatment in certain countries hampers growth of the global colon and rectal cancer drugs market. For instance, according to the comparison study published in the American Society of Clinical Oncology (ASCO) 2018 meeting, treatment cost of metastatic colorectal cancer in Western Washington (U.S.) is higher than the province of British Columbia (BC) in Canada, with no significant difference in the outcome.
Colon and Rectal Cancer Drugs Market – Regional Analysis
On the basis of region, the global colon and rectal cancer drugs market is segmented into North America, Latin America, Europe, Middle East, Asia Pacific, and Africa. North America holds dominant position in the colon and rectal cancer drugs market, followed by Europe. This is owing to increasing incidence rate of colorectal cancer in these regions. According to the World Cancer Research Fund International, in 2012, Republic of Korea had the highest rate of colorectal cancer, followed by Slovakia and Hungary. Furthermore, since few years, large number of colorectal cancer incidences were registered in Oceania and Europe region, while it shows lowest incidence rates in Africa and Asia region.
Access Table of Content (TOC) Of the Report @ https://www.coherentmarketinsights.com/ongoing-insight/toc/2019
Colon and Rectal Cancer Drugs Market – Competitive Analysis
Some of the key players operating in the global colon and rectal cancer drugs market include Amgen Inc., AstraZeneca plc, Bayer AG, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo Company, Merck KGaA, Novartis International AG, Sirtex Medical Limited, Sanofi S.A. Sorrento Therapeutics, and Takeda Pharmaceutical Company Ltd. Key players in the market are involved in research and development activities to conduct clinical trial studies and to gain regulatory approval. For instance, in March 2018, Daiichi Sankyo initiated phase II study of DS-8201 in patients with HER2-expressing advanced colorectal cancer. Currently, there is no HER2 –targeting therapy approved for patients suffering from HER2- expressing colorectal cancer. Initiation of HER2 phase clinical trial study by Daiichi Sankyo for colorectal cancer treatment will help to improve the outcomes in colorectal cancer patients. In March 2018, FDA approved Bristol-Myers Squibb’s Opdivo (nivolumab) injection, which is administrated intravenously for the treatment of adult and pediatric (12 years and older) patients who suffer from microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer.
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Colon and Rectal Cancer Drugs Market Opportunity Analysis, 2018 – 2026 here
News-ID: 1197707 • Views: 253
More Releases from Coherent Market Insights
Land Mobile Radio (LMR) Systems Market - How COVID19 impacting on the Informatio …
United States,Washington: Latest release from CMI with title Land Mobile Radio (LMR) Systems research Report 2019-2026 (by Product Type, End-User / Application and Regions / Countries) provides an in-depth assessment of the Land Mobile Radio (LMR) Systems including key market trends, upcoming technologies, industry drivers, challenges, regulatory policies, key players company profiles and techniques. Global Land Mobile Radio (LMR) Systems Market study with 100+ market data Tables, Pie Chat, Graphs
Computational Biology Market - Detailed Analysis of Current and Future Industry …
Global Computational Biology Market Insights, Forecast to 2027 is latest research study re-leased by CMI evaluating the market, highlighting opportunities, risk side analysis, and lever-aged with strategic and tactical decision-making support. The study provides information on market trends and development, drivers, capacities, technologies, and on the changing investment structure of the Global Computational Biology Market. Some of the key players profiled in the study are Accelrys, Certara, L.P., Chemical Computing
Telerehabilitation Systems Market - Detailed Analysis of Current and Future Indu …
Global Telerehabilitation Systems Market Insights, Forecast to 2027 is latest research study re-leased by CMI evaluating the market, highlighting opportunities, risk side analysis, and lever-aged with strategic and tactical decision-making support. The study provides information on market trends and development, drivers, capacities, technologies, and on the changing investment structure of the Global Telerehabilitation Systems Market. Some of the key players profiled in the study are Reflexion Health, Inc., 270 Vision
Personal Emergency Response Systems Market - Detailed Analysis of Current and Fu …
Global Personal Emergency Response Systems Market Insights, Forecast to 2027 is latest research study re-leased by CMI evaluating the market, highlighting opportunities, risk side analysis, and lever-aged with strategic and tactical decision-making support. The study provides information on market trends and development, drivers, capacities, technologies, and on the changing investment structure of the Global Personal Emergency Response Systems Market. Some of the key players profiled in the study are Koninklijke
More Releases for Cancer
Cancer Vaccines Market
Manufacturers in the cancer vaccines market are focusing on developing new vaccines in order to treat various cancers. Through this, they are expected to gain a competitive edge in the market and increase their market share. For instance, Gilead Science Inc., in 2017, acquired Kite Pharma Inc., which is involved in development of different type of immunotherapy and vaccines. Also, Treos Bio, in 2017, collaborated with Pharmaceutical Product Development, LLC
Cancer Molecular Biomarkers Market
Cancer molecular biomarkers refer to naturally-occurring molecules or genes in living organisms, which is an indicator for the presence of cancer in the body. A biomarker is a measurable indicator of biological process, condition, or disease and can be found in the blood, tissues, or other body fluids. Cancer molecular biomarkers help to diagnose cancer and monitor patients’ responses to treatments. On the basis of diagnostics, the cancer molecular
Cancer Diagnostics Global Market: By Application - Breast Cancer, Lung Cancer, C …
Researchmoz added Most up-to-date research on "Cancer Diagnostics Global Market: By Application - Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma & Other Cancers" to its huge collection of research reports. This report studies Cancer Diagnostics in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top
Global Cancer Vaccines Market 2016: Liver cancer, Cervical cancer, Stomach cance …
Latest industry research report on Cancer vaccines are the type of immunotherapy (also named as biologic therapy), designed to boost body's natural defense against cancer. The body's natural immune system recognizes vaccine proteins as the foreign particles and sets up an immunity against them. According to World Health Organization (WHO), cancer is a leading cause of worldwide mortality registering ~14 million new cases and ~8.2 million cancer-related diseases in 2012. Personalized
Taking thyroid cancer seriously
With the increasing incidence rate of thyroid cancer in Metro Cebu, the Eduardo J. Aboitiz Cancer Center (EJACC) of the Ramon Aboitiz Foundation Inc. (RAFI) urged the public to undergo early screening and prevention measures to fight the disease. “Thyroid cancer is high on prognosis. It is preventable through various screening methods, such as physical examination and ultrasound of the neck, as well as some prevention measures, including regular exercise and
Immune System Challenges Cancer
Cancer, as a word is in itself potent enough to send cold shivers down the spine of the readers. The trauma that the cancer patients go through in various treatments medical science has traditionally offered for this menace justifies the fear for it. Add to it the relatively low rates of survival and one would not be surprised to know that it is a leading cause of deaths. Scientific experiments